LGM Pharma API Sourcing. CDMO Services, Regulatory Expertise. LGM Pharma API Sourcing. CDMO Services, Regulatory Expertise.

X

Find the latest Drugs in Development and Pipeline Prospector News of OrsoBio.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
OrsoBio
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
Palo Alto, CA
Telephone
Telephone

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore in development for the treatment of obesity and obesity-associated diseases, including diabetes and NASH.


Lead Product(s): TLC-6740

Therapeutic Area: Nutrition and Weight Loss Product Name: TLC-6740

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 05, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TLC-3595 is a novel and selective ACC2 inhibitor designed to treat type 2 diabetes by increasing FAO, reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver


Lead Product(s): TLC-3595

Therapeutic Area: Endocrinology Product Name: TLC-3595

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 20, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

OrsoBio has recently acquired novel compounds and intellectual property for four programs, including inhibitors of acetyl-CoA carboxylase-2 (TLC-3595), liver X receptor, and aminocarboxymuconate semialdehyde decarboxylase, as well as a portfolio of mitochondrial protonophores.


Lead Product(s): TLC-3595

Therapeutic Area: Endocrinology Product Name: TLC-3595

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 03, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

ACMSD is a key enzyme involved in the de novo synthesis of NAD+, which is critical to mitochondrial function via maintenance of cellular redox state. TLC-065, is being advanced for the treatment of a range of metabolic and inflammatory liver and kidney disorders.


Lead Product(s): TLC-065

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TLC-065

Highest Development Status: PreclinicalProduct Type: Undisclosed

Recipient: Mitobridge

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition November 02, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TLC-3595 (formerly S-723595), a novel and selective ACC2 inhibitor, is designed to treat type 2 diabetes by increasing fatty acid oxidation (FAO), reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver.


Lead Product(s): TLC-3595

Therapeutic Area: Endocrinology Product Name: TLC-3595

Highest Development Status: Phase IProduct Type: Undisclosed

Recipient: Shionogi

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition November 02, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TLC-2716 is a liver-targeted, inverse agonist of LXR that regulates plasma triglycerides and cholesterol via multiple mechanisms, including inhibition of DNL, increased clearance of triglyceride- and cholesterol-rich lipoproteins, and reduced intestinal lipid absorption.


Lead Product(s): TLC-2716

Therapeutic Area: Cardiology/Vascular Diseases Product Name: TLC-2716

Highest Development Status: Phase IProduct Type: Small molecule

Recipient: Phenex Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition November 02, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TLC-1235, a novel, controlled-release mitochondrial protonophore, increases energy expenditure and is expected to have broad, systemic metabolic and cardiovascular benefits, including improved insulin sensitivity, NASH, dyslipidemia, and weight loss.


Lead Product(s): TLC-1235

Therapeutic Area: Dermatology Product Name: TLC-1235

Highest Development Status: PreclinicalProduct Type: Undisclosed

Partner/Sponsor/Collaborator: Yale University

Deal Size: $2.3 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement November 02, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TLC-6740 is a novel, liver-targeted mitochondrial protonophore in development for the treatment of severe lipodystrophies and other metabolic disorders. Based on active hepatic uptake and mitochondrial protonophoric activity.


Lead Product(s): TLC-6740

Therapeutic Area: Dermatology Product Name: TLC-6740

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: Samsara BioCapital

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 02, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

TLC-2716 is a liver-targeted inverse agonist of the Liver X Receptor (LXR) for the treatment of severe hypertriglyceridemia, familial hypercholesterolemia and NASH.


Lead Product(s): TLC-2716

Therapeutic Area: Cardiology/Vascular Diseases Product Name: TLC-2716

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 01, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY